SEATTLE, WA--(Marketwire - October 04, 2007) - Targeted Genetics Corporation (NASDAQ: TGEN) today announced that it has received a milestone payment from Amsterdam Molecular Therapeutics B.V. (AMT). The payment was made under a licensing agreement that provides AMT with non-exclusive rights to patents covering Adeno-Associated Virus type 1 (AAV1), a serotype of AAV with potential application in the development and commercialization of therapeutic products for the treatment of lipoprotein lipase (LPL) deficiency. AMT recently reported the initiation of a pre-registration clinical trial in Canada for AMT-011, an AAV1-based therapy for LPL deficiency, and anticipates commercial roll-out of the product in 2009. LPL deficiency in humans is a severe and debilitating disease associated with extremely high serum triglyceride concentrations, high morbidity, and increased mortality. The amount of the milestone payment is not disclosed.
